Evidence map›Paper›PMID 39294194›Full record

ArticleScientific reports2024

Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.

Ruth Luthi-Carter, Sara Cappelli, Morgan Le Roux-Bourdieu, Noemie Tentillier, James P Quinn, Tiziana Petrozziello, Lathika Gopalakrishnan, Purva Sethi, Himanshi Choudhary, Giorgia Bartolini and 19 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Ruth Luthi-CarterAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland. ruth.luthi-carter@acimmune.com.
Sara CappelliInternational Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149, Trieste, Italy.
Morgan Le Roux-BourdieuAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Noemie TentillierAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
James P QuinnMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Tiziana PetrozzielloSean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, 165 Cambridge Street, Boston, MA, 02114, USA.
Lathika GopalakrishnanDepartment of Translational Neuroscience, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ, 85013, USA.
Purva SethiKansas City University, 1750 Independence Ave, Kansas City, MO, 64106, USA.
Himanshi ChoudharyInternational Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149, Trieste, Italy.
Giorgia BartoliniAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Elias GebaraAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Cristiana StuaniInternational Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149, Trieste, Italy.
Laure FontAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Jiyan AnDepartment of Translational Neuroscience, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ, 85013, USA.
Vanessa OrtegaDepartment of Translational Neuroscience, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ, 85013, USA.
Jessica SageKansas City University, 1750 Independence Ave, Kansas City, MO, 64106, USA.
Edina KosaKansas City University, 1750 Independence Ave, Kansas City, MO, 64106, USA.
Bianca A TrombettaMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Roberto SimeoneDipartimento di Medicina Trasfusionale Giuliano-Isontina, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Italy.
Tamara SeredeninaAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Tariq AfrozAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
James D BerryMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Steven E ArnoldMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Becky C CarlyleMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Oskar AdolfssonAC Immune, SA (ACIU), EPFL Innovation Park Building B, 1015, Lausanne, Switzerland.
Ghazaleh Sadri-VakiliMassachusetts General Hospital Department of Neurology, 114 16th Street, Charlestown, MA, 02129, USA.
Emanuele BurattiInternational Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149, Trieste, Italy.
Robert BowserDepartment of Translational Neuroscience, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ, 85013, USA.
Abdulbaki AgbasKansas City University, 1750 Independence Ave, Kansas City, MO, 64106, USA.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
NIA NIH HHS P30 AG062421Target ALS Foundation BB-2022-C5Target ALS Foundation Industry-Led Consortium Project Grant
6 · The paper itself

Abstract

The TAR DNA Binding Protein 43 (TDP-43) has been implicated in the pathogenesis of human neurodegenerative diseases and exhibits hallmark neuropathology in amyotrophic lateral sclerosis (ALS). Here, we explore its tractability as a plasma biomarker of disease and describe its localization and possible functions in the cytosol of platelets. Novel TDP-43 immunoassays were developed on three different technical platforms and qualified for specificity, signal-to-noise ratio, detection range, variation, spike recovery and dilution linearity in human plasma samples. Surprisingly, implementation of these assays demonstrated that biobank-archived plasma samples yielded considerable heterogeneity in TDP-43 levels. Importantly, subsequent investigation attributed these differences to variable platelet recovery. Fractionations of fresh blood revealed that ≥ 95% of the TDP-43 in platelet-containing plasma was compartmentalized within the platelet cytosol. We reasoned that this highly concentrated source of TDP-43 comprised an interesting substrate for biochemical analyses. Additional characterization of platelets revealed the presence of the disease-associated phosphoserine 409/410 TDP-43 proteoform and many neuron- and astrocyte-expressed TDP-43 mRNA targets. Considering these striking similarities, we propose that TDP-43 may serve analogous functional roles in platelets and synapses, and that the study of platelet TDP-43 might provide a window into disease-related TDP-43 dyshomeostasis in the central nervous system.

Indexed as

Biological Specimen BanksBlood PlateletsDNA-Binding ProteinsNeurodegenerative DiseasesAmyotrophic Lateral SclerosisBiomarkersCytosolHumansBiomarkersDNA-Binding ProteinsTARDBP protein, human

Identifiers

PMID39294194
PMCPMC11410945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.